Literature DB >> 25326807

Cripto-1 expression and its prognostic value in human bladder cancer patients.

Bingbing Wei1, Wei Jin, Jun Ruan, Zhuoqun Xu, You Zhou, Jiabei Liang, Huan Cheng, Ke Jin, Xing Huang, Peng Lu, Qiang Hu.   

Abstract

Cripto-1 is an important embryonic gene that involved in self-renewal and maintenance of pluripotency of stem cells. Overexpression of Cripto-1 has been found to be correlated with tumorigenesis and may affect tumor recurrence and metastasis. The previous studies indicate that Cripto-1 might be a potential prognostic biomarker for several malignancies. The aim of this study is to examine Cripto-1 expression pattern and clinicopathological significance in human bladder cancer patients. We investigated Cripto-1 expression in 30 paired bladder cancer tissues and corresponding noncancerous bladder tissues using real-time quantitative RT-PCR (qRT-PCR). Moreover, Cripto-1 expression in 130 bladder cancer specimens and bladder cancer T24 and 5637 cells were analyzed using immunohistochemistry and immunofluorescence assays. The recurrence/metastasis-free survival was assessed by Kaplan-Meier method and log-rank test. Cox regression was also used for univariate and multivariate analyses of prognostic factors. The results showed that Cripto-1 expression is increased in bladder cancer tissues and is significantly associated with tumor size (P = 0.005) and tumor grade (P = 0.035). In addition, the expression level of Cripto-1 in bladder cancer was also found to be significantly associated with SRY-related HMG-box gene 2 expression (P = 0.003) and Ki-67 (P = 0.001). Compared with the patients with low Cripto-1 expression, the patients with high Cripto-1 expression had significantly poorer recurrence/metastasis-free survival (P = 0.011). Cox regression showed that Cripto-1 might be an independent prognostic factor for recurrence/metastasis-free survival (P = 0.036). Our findings suggest that high Cripto-1 expression might be involved in the development of bladder cancer and a potentially effective prognostic marker in bladder cancer patients.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25326807     DOI: 10.1007/s13277-014-2695-1

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  50 in total

Review 1.  Ovarian cancer stem cells.

Authors:  A G Zeimet; D Reimer; S Sopper; M Boesch; A Martowicz; J Roessler; A M Wiedemair; H Rumpold; G Untergasser; N Concin; G Hofstetter; E Muller-Holzner; H Fiegl; C Marth; D Wolf; M Pesta; J Hatina
Journal:  Neoplasma       Date:  2012       Impact factor: 2.575

Review 2.  Regulation of self-renewal in normal and cancer stem cells.

Authors:  Maria V Verga Falzacappa; Chiara Ronchini; Linsey B Reavie; Pier G Pelicci
Journal:  FEBS J       Date:  2012-08-24       Impact factor: 5.542

3.  The role of Cripto-1 in the tumorigenesis and progression of oral squamous cell carcinoma.

Authors:  Hye-Jung Yoon; Ji-Soo Hong; Wui-Jung Shin; Yoo-Jin Lee; Kyoung-Ok Hong; Jae-Il Lee; Sam-Pyo Hong; Seong-Doo Hong
Journal:  Oral Oncol       Date:  2011-08-06       Impact factor: 5.337

4.  CD13 is a therapeutic target in human liver cancer stem cells.

Authors:  Naotsugu Haraguchi; Hideshi Ishii; Koshi Mimori; Fumiaki Tanaka; Masahisa Ohkuma; Ho Min Kim; Hirofumi Akita; Daisuke Takiuchi; Hisanori Hatano; Hiroaki Nagano; Graham F Barnard; Yuichiro Doki; Masaki Mori
Journal:  J Clin Invest       Date:  2010-08-09       Impact factor: 14.808

Review 5.  Breast cancer stem cells: an update.

Authors:  Jabed Iqbal; Pek Yoon Chong; Puay Hoon Tan
Journal:  J Clin Pathol       Date:  2013-01-15       Impact factor: 3.411

6.  Prognostic factors including Ki-67 and p53 in Bacillus Calmette-Guérin-treated non-muscle-invasive bladder cancer: a prospective study.

Authors:  Marco Oderda; Fulvio Ricceri; Francesca Pisano; Chiara Fiorito; Alberto Gurioli; Giovanni Casetta; Andrea Zitella; Donatella Pacchioni; Paolo Gontero
Journal:  Urol Int       Date:  2013-01-17       Impact factor: 2.089

Review 7.  Understanding the cancer stem cell.

Authors:  S Bomken; K Fiser; O Heidenreich; J Vormoor
Journal:  Br J Cancer       Date:  2010-07-27       Impact factor: 7.640

8.  Biological and molecular heterogeneity of breast cancers correlates with their cancer stem cell content.

Authors:  Salvatore Pece; Daniela Tosoni; Stefano Confalonieri; Giovanni Mazzarol; Manuela Vecchi; Simona Ronzoni; Loris Bernard; Giuseppe Viale; Pier Giuseppe Pelicci; Pier Paolo Di Fiore
Journal:  Cell       Date:  2010-01-08       Impact factor: 41.582

Review 9.  Molecular pathogenesis of bladder cancer.

Authors:  Margaret A Knowles
Journal:  Int J Clin Oncol       Date:  2008-08-15       Impact factor: 3.402

10.  Monoclonal antibodies against recombinant parts of the Ki-67 antigen (MIB 1 and MIB 3) detect proliferating cells in microwave-processed formalin-fixed paraffin sections.

Authors:  G Cattoretti; M H Becker; G Key; M Duchrow; C Schlüter; J Galle; J Gerdes
Journal:  J Pathol       Date:  1992-12       Impact factor: 7.996

View more
  8 in total

1.  Cripto-1 is overexpressed in carcinoma ex pleomorphic adenoma of salivary gland.

Authors:  Leorik Pereira Silva; Luiz Arthur Barbosa da Silva; Bruno Tavares Sedassari; Suzana Cantanhede Orsini Machado de Sousa; Joabe Dos Santos Pereira; Lélia Batista de Souza; Márcia Cristina da Costa Miguel
Journal:  Eur Arch Otorhinolaryngol       Date:  2018-03-29       Impact factor: 2.503

2.  Biological and Clinicopathological Significance of Cripto-1 Expression in the Progression of Human ESCC.

Authors:  Reihaneh Alsadat Mahmoudian; Mohammad Reza Abbaszadegan; Mohammad Mahdi Forghanifard; Meysam Moghbeli; Faezeh Moghbeli; Jamshidkhan Chamani; Mehran Gholamin
Journal:  Rep Biochem Mol Biol       Date:  2017-04

3.  Elevated expression of Cripto-1 correlates with poor prognosis in hepatocellular carcinoma.

Authors:  Jia-Hong Wang; Wei Wei; Jing Xu; Zhi-Xing Guo; Cheng-Zuo Xiao; Yong-Fa Zhang; Pei-En Jian; Xiao-Liang Wu; Ming Shi; Rong-Ping Guo
Journal:  Oncotarget       Date:  2015-10-27

4.  Cripto-1 expression in patients with clear cell renal cell carcinoma is associated with poor disease outcome.

Authors:  Yi-Jun Xue; Song-Ning Chen; Wei-Guang Chen; Geng-Qing Wu; Yun-Feng Liao; Jian-Bin Xu; Hao Tang; Shui-Hua Yang; Shui-Yong He; Yun-Fei Luo; Zhi-Hui Wu; Hai-Wen Huang
Journal:  J Exp Clin Cancer Res       Date:  2019-08-27

5.  High level of serum Cripto-1 in hepatocellular carcinoma, especially with hepatitis B virus infection.

Authors:  Yingyu Zhang; Hongqin Xu; Xiumei Chi; Yuxiang Fan; Ying Shi; Junqi Niu
Journal:  Medicine (Baltimore)       Date:  2018-08       Impact factor: 1.817

6.  CRIPTO Is a Marker of Chemotherapy-Induced Stem Cell Expansion in Non-Small Cell Lung Cancer.

Authors:  Federica Francescangeli; Maria Laura De Angelis; Rachele Rossi; Giovanni Sette; Adriana Eramo; Alessandra Boe; Ombretta Guardiola; Tao Tang; Shi-Cang Yu; Gabriella Minchiotti; Ann Zeuner
Journal:  Front Oncol       Date:  2022-06-02       Impact factor: 5.738

Review 7.  TGF-β superfamily co-receptors in cancer.

Authors:  John B Pawlak; Gerard C Blobe
Journal:  Dev Dyn       Date:  2021-04-09       Impact factor: 3.780

8.  Clinical significance of cripto-1 expression in lung adenocarcinoma.

Authors:  Hua Zhang; Bin Zhang; Liuwei Gao; Lianmin Zhang; Kaikai Zhu; Runfen Cheng; Changli Wang
Journal:  Oncotarget       Date:  2017-02-27
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.